Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia

Sayyad S. Siddiqui, Deepali Laxman Jaybhaye, Anjali Kale, Jagannath Kakade, Madhuri Engade, Mahd. Haseeb


Background: Iron deficiency anemia is common problem in children, though the oral iron therapy is the main stay of treatment, but most of children not responding to it due to non-compliance. So the parental iron therapy is the treatment of choice for it.

Methods: Fifty children between the age group of 1-17 years of age were selected for this study diagnosed as iron deficiency anemia. Iron sucrose given by IV according to their weight and age. CBC performed before starting of study and after receiving Iron sucrose intravenously i.e. after 4, 10 and 30 days of iron sucrose.  

Results: Among the red cell indices, mean corpuscular volume and mean corpuscular haemoglobin in this study we got mark improvement in both the parameters along with improvement in PCV and finally increase in haemoglobin level. All the parameters having P value highly significant i.e. <0.001 along with minimal side effects.

Conclusions: Iron sucrose can be safely used in children.


Iron deficiency anemia, Iron sucrose, Haemoglobin

Full Text:



Demaeyer E. Preventing and controlling iron deficiency anemia through primary health care. In: Demaeyer E, eds. A Guide for Health Administrators and Program Managers. Switzerland: World Health Organization; 1989: 27.

Bilenko N, Yehiel M, Inbar Y, Gazala E. The association between anemia in infants and maternal knowledge and adherence with iron supplementation in southern Israel. Isr Med Assoc J. 2007;9:521-4.

ACC/SCN, IFPRI. Fourth report on the world nutrition situation. In: ACC/SCN, eds. ACC/SCN Report. Geneva: ACC/SCN; 2000: 21-7.

Meyerovitch J, Sherf M, Antebi F, Barhoum-Noufi M, Horev Z, Jaber L, et al. The incidence of anemia in an Israeli population: a population analysis for anemia in 34512 Israeli infants aged 9 to 18 months. Pediatrics. 2006;118(4):e1055-60.

American Academy of Pediatric Committee on Nutrition. The use of whole cow’s milk in infancy. Pediatrics. 1992;89:1105-9.

Bailie GR, Johnson CA, Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis. 2000;35:1-12.

Shimada A. Adverse reactions to total-dose infusion of iron dextran. Clin Pharm. 1982;1:248-9.

Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Saf. 1997;17:241-50.

Rosenlof K, Kivivuori SM, Gronhagen-Riska C, Teppo AM, Slimes MA. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol. 1995;43:249-55.

Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis. 1999;33:464-70.

Van Wyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis. 2000;36:88-97.

Notebaert E, Chauny JM, Albert M, Fortier S, Leblanc N, Williamson DR. Short-term benefits and risks of intravenous iron: a systematic review and meta-analysis. Transfusion. 2007;47:1905-18.

Morgan HE, Holt RC, Jones CA, Judd BA. Intravenous iron treatment in pediatric chronic kidney disease patients not on erythropoietin. Pediatr Nephrol. 2007;22:1963-5.

Kosch M, Bahner U, Bettger H, Matzkies F, Teschner M, Schaefer RM. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs. iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001;16:1239-44.

Silverberg DS, Blum M, Agbaria Z, Schwartz D, Zubkov A, Yachnin T, et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl. 1999;69:S79-85.

al-Momen AK, al-Meshari A, al-Nuaim L, Saddique A, Abotalib Z, Khashogji T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1996;69:121-4.

Lanzkowsky P. Iron deficiency anemia. In: Pediatric Hematology-Oncology. 3rd ed. San Diego: Academic Press; 2000: 48.18.

Kliegman RM, Behrman RE, Jenson HB, Stanton BF. Table 715-6. In: Kliegman RM, Behrman RE, Jenson HB, Stanton BF, eds. Nelson Textbook of Pediatrics. 18th ed. Philadelphia: WB Saunders; 2007: 2944.

Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidney Dis. 2001;38:988-91.

Hershko C, Hoffbrandt AV, Keret D, Souroujon M, Maschler I, Monselise Y, et al. Role of autoimmune gastritis, Helicobacter pylori and celiac disease in refractory or unexplained iron deficiency anemia. Hematologica. 2005;90:585-95.

Mamula P, Piccoli DA, Peck SN, Markowitz JE, Baldassano RN. Total dose intravenous infusion of iron dextran for iron-deficiency anemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;34:286-90.

Berniere J, Dehullu JP, Gall O, Murat I. Intravenous iron in the treatment of post-operative anemia in surgery of the spine in infants and adolescents. Rev Chir Orthp Reperat Appar Mot. 1998;84:319-22.

Akarsu S, Taskin E, Yilmaz E, Kilic M, Aygun AD. Treatment of iron deficiency anemia with intravenous iron preparatiovs. Acta Hematol. 2006;116:51-7.

Pollak A, Hayde M, Hayn M, Herkner K, Lombard KA, Lubec G, et al. Effect of intravenous iron supplementation on erythropoiesis in erythropoietin-treated premature infants. Pediatrics. 2001;107:78-85.

Koorts AM, Viljoen M. Ferritin and ferritin isoforms. I. Structurefunction relationship, synthesis, degradation and secretion. Arch Physiol Biochem. 2007;113:30-54.